News | January 01, 2025
Anthem Biosciences files DRHP for Rs. 3,395 crore IPO
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
The company will receive GMP compliance certificate which will further help to accelerate the business growth across the globe
The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
The centre features a cutting-edge climatic chamber for stability testing and spectrophotometry to ensure that products meet the most stringent manufacturing and testing standards
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Total Income in Q2 FY25 stood at Rs. 532.18 crore
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Subscribe To Our Newsletter & Stay Updated
